ArticleJournal of experimental & clinical cancer research : CR2015
Neuron navigator 2 overexpression indicates poor prognosis of colorectal cancer and promotes invasion through the SSH1L/cofilin-1 pathway.
Article in Journal of experimental & clinical cancer research : CR, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 38 citations in OpenAlex.
- Exploration of potential biomarkers in salivary duct carcinoma based on bioinformatics analysis.Scientific reports · 2026Article
- Establishment of a mInternational journal of genomics · 2026Article
- GP73-dependent regulation of exosome biogenesis promotes colorectal cancer liver metastasis.Molecular cancer · 2025Article
- GILT stabilizes cofilin to promote the metastasis of prostate cancer.Cell death discovery · 2025Article
- Chromosome 12 Open Reading Frame 49 Promotes Tumor Growth and Predicts Poor Prognosis in Colorectal Cancer.Digestive diseases and sciences · 2023Article
- Mangiferin inhibits chronic stress-induced tumor growth in colorectal liver metastases via WAVE2 signaling pathway.Heliyon · 2023Article
- Active forgetting requires Sickie function in a dedicated dopamine circuit inProceedings of the National Academy of Sciences of the United States of America · 2022Article
- STAT3-NAV2 axis as a new therapeutic target for rheumatoid arthritis via activating SSH1L/Cofilin-1 signaling pathway.Signal transduction and targeted therapy · 2022Article
- Identification of ITPR1 as a Hub Gene of Group 3 Medulloblastoma and Coregulated Genes with Potential Prognostic Values.Journal of molecular neuroscience : MN · 2022Article
- Article
- The Neuron Navigators: Structure, function, and evolutionary history.Frontiers in molecular neuroscience · 2022Review
- Signature Panel of 11 Methylated mRNAs and 3 Methylated lncRNAs for Prediction of Recurrence-Free Survival in Prostate Cancer Patients.Pharmacogenomics and personalized medicine · 2021Article
- Follistatin-Like 3 Enhances Invasion and Metastasis via β-Catenin-Mediated EMT and Aerobic Glycolysis in Colorectal Cancer.Frontiers in cell and developmental biology · 2021Article
- WAVE2 Enhanced Hepatic Stellate Cells Activity in Colorectal Liver Metastases.Cancer management and research · 2020Article
- SSH1 expression is associated with gastric cancer progression and predicts a poor prognosis.BMC gastroenterology · 2018Article
- SMYD5 Controls Heterochromatin and Chromosome Integrity during Embryonic Stem Cell Differentiation.Cancer research · 2017Article
- Family-based association analysis of NAV2 gene with the risk and age at onset of Alzheimer's disease.Journal of neuroimmunology · 2017Article
- Neuron navigator-2 and cyclin D2 are new candidate prognostic markers in uterine sarcoma.Virchows Archiv : an international journal of pathology · 2017Article
- Overexpression of proteasomal activator PA28α serves as a prognostic factor in oral squamous cell carcinoma.Journal of experimental & clinical cancer research : CR · 2016Article
- Discovery of a Family of Genomic Sequences Which Interact Specifically with the c-MYC Promoter to Regulate c-MYC Expression.PloS one · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNeuron navigator 2 (NAV2) encodes a member of the neuron navigator gene family, which plays a role in tumorigenesis and cell migration. However, the prognostic value of NAV2 expression in colorectal cancer (CRC) patients and the potential pathway through which NAV2 promotes migration and invasion in CRC cell lines is poorly understood.
methodsThe expression level of NAV2 was detected in CRC tissues from two different CRC cohorts by immunohistochemistry, qRT-PCR and Western blotting; the correlation between NAV2 expression and clinicopathological characters was analyzed, and the prognostic value of NAV2 expression was analyzed using a Cox regression model. CRC cell lines with NAV2 knocked out were used to validate the function and potential pathway used by NAV2 to promote CRC cell migration and invasion.
resultsThe results showed that NAV2 was overexpressed in CRC tissues, and it was closely correlated with depth of invasion, and lymph and distant metastasis. Multivariate analysis indicated that high NAV2 expression was a poor prognostic indicator of recurrence-free survival and overall survival in CRC patients. Furthermore, Cox regression analysis revealed that high NAV2 expression integrated with high tumor budding grade was a powerful independent predictive factor of CRC clinical outcome. In vitro and in vivo assays demonstrated that knockdown of NAV2 led to reduced migration and invasion of cancer cells, and the process involved the regulation of F-actin polymerization through the SSH1L/cofilin-1 pathway.
conclusionBased on these findings, NAV2 could serve as both a prognostic biomarker and a potential therapeutic target for patients with NAV2-positive CRC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.